Shares of BioAge Labs, Inc. (BIOA) are up by 7.25% at $4.43 following the announcement of a multi-year research collaboration with Novartis (NVS) to discover novel targets for therapies that address age-related diseases and conditions.
Under the agreement, BioAge will receive up to $20 million in upfront payments and research funding, plus up to $530 million in potential future research, development, and commercial milestones.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com